Patents by Inventor Fernando Dangond

Fernando Dangond has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CLADRIBINE REGIMEN FOR TREATING PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS
    Publication number: 20250241938
    Abstract: Specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine can be effective for the treatment of progressive forms of Multiple Sclerosis, especially Primary Progressive Multiple Sclerosis and/or Secondary Progressive Multiple Sclerosis. Methods of treatment can be based on specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine.
    Type: Application
    Filed: March 4, 2025
    Publication date: July 31, 2025
    Applicant: ARES TRADING S.A.
    Inventors: Fernando Dangond, Matthias Dotzauer
  • Cladribine regimen for treating progressive forms of multiple sclerosis
    Patent number: 12268703
    Abstract: Specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine can be effective for the treatment of progressive forms of Multiple Sclerosis, especially Primary Progressive Multiple Sclerosis and/or Secondary Progressive Multiple Sclerosis. Methods of treatment can be based on specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: April 8, 2025
    Assignee: ARES TRADING S.A.
    Inventors: Fernando Dangond, Matthias Dotzauer
  • Cladribine regimen for treating progressive forms of Multiple Sclerosis
    Publication number: 20230021880
    Abstract: Specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine can be effective for the treatment of progressive forms of Multiple Sclerosis, especially Primary Progressive Multiple Sclerosis and/or Secondary Progressive Multiple Sclerosis. Methods of treatment can be based on specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine.
    Type: Application
    Filed: September 16, 2022
    Publication date: January 26, 2023
    Applicant: Merck Patent GmbH
    Inventors: Fernando DANGOND, Matthias Dotzauer
  • Cladribine regimen for treating progressive forms of Multiple Sclerosis
    Publication number: 20210169912
    Abstract: Specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine can be effective for the treatment of progressive forms of Multiple Sclerosis, especially Primary Progressive Multiple Sclerosis and/or Secondary Progressive Multiple Sclerosis. Methods of treatment can be based on specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine.
    Type: Application
    Filed: October 23, 2020
    Publication date: June 10, 2021
    Applicant: Merck Patent GmnH
    Inventors: Fernando Dangond, Matthias Dotzauer
  • Cladribine regimen for treating progressive forms of multiple sclerosis
    Patent number: 10849919
    Abstract: Specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine can be effective for the treatment of progressive forms of Multiple Sclerosis, especially Primary Progressive Multiple Sclerosis and/or Secondary Progressive Multiple Sclerosis. Methods of treatment can be based on specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: December 1, 2020
    Assignee: Merck Patent GmbH
    Inventors: Fernando Dangond, Matthias Dotzauer
  • Cladribine regimen for treating progressive forms of Multiple Sclerosis
    Publication number: 20190167707
    Abstract: Specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine can be effective for the treatment of progressive forms of Multiple Sclerosis, especially Primary Progressive Multiple Sclerosis and/or Secondary Progressive Multiple Sclerosis. Methods of treatment can be based on specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine.
    Type: Application
    Filed: November 23, 2018
    Publication date: June 6, 2019
    Applicant: Merck Patent GmbH
    Inventors: Fernando Dangond, Matthias Dotzauer
  • Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
    Publication number: 20040156826
    Abstract: The present invention identifies a number of gene markers whose expression is altered in multiple sclerosis (MS). These markers can be used to diagnose or predict MS in subjects, and can be used in the monitoring of therapies. In addition, these genes identify therapeutic targets, the modification of which may prevent MS development or progression.
    Type: Application
    Filed: September 25, 2003
    Publication date: August 12, 2004
    Inventors: Fernando Dangond, Daehee Hwang, Steven R. Gullans
  • Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease
    Publication number: 20040077591
    Abstract: The present invention provide therapies for Alzheimer's Disease (AD), multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). The method relies on the use of an HDAC inhibitor, alone or in combination with other drugs, to prevent or treat AD, MS or ALS. Also provided are methods of screening for additional HDAC inhibitors with particular efficacy against these disease states.
    Type: Application
    Filed: March 27, 2003
    Publication date: April 22, 2004
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventor: Fernando Dangond
  • Identification of dysregulated genes in patients with multiple sclerosis
    Publication number: 20040018522
    Abstract: The present invention identifies a number of gene markers whose expression is altered in multiple sclerosis (MS). These markers can be used to diagnose or predict MS in subjects, and can be used in the monitoring of therapies. In addition, these genes identify therapeutic targets, the modification of which may prevent MS development or progression.
    Type: Application
    Filed: May 6, 2003
    Publication date: January 29, 2004
    Applicant: Brigham and Women's Hospital, Inc.
    Inventors: Fernando Dangond, Daehee Hwang